Literature DB >> 26864621

Salvage Treatment of Mucormycosis Post-Liver Transplant With Posaconazole During Sirolimus Maintenance Immunosuppression.

Jennifer C Deyo1, Nicole Nicolsen2, Anne Lachiewicz3, Tomasz Kozlowski4.   

Abstract

We describe the first successful case of posaconazole salvage therapy for mucormycosis with concomitant sirolimus (SRL) maintenance immunosuppression following liver transplantation, despite black box drug interaction following intolerance to first-line tacrolimus and amphotericin due to nephrotoxicity and neurotoxicity. This case describes a 55-year-old female who developed rhinocerebral mucormycosis 108 days after liver transplantation. After 3 months of posaconazole therapy, the patient remains free of disease at 3 years posttransplant. This case report illustrates successful resolution of mucormycosis without SRL toxicity to resolve nephrotoxicity of long-term amphotericin on top of already nephrotoxic immunosuppression. With higher bioavailability of recently FDA-approved posaconazole delayed release tablets, this azole may be a therapeutic option for transplant patients who need to remain on CYP3A4-metabolized immunosuppressive agents.

Entities:  

Keywords:  immunosuppression; liver transplantation; mucormycosis; zygomycosis

Mesh:

Substances:

Year:  2016        PMID: 26864621     DOI: 10.1177/0897190016628702

Source DB:  PubMed          Journal:  J Pharm Pract        ISSN: 0897-1900


  3 in total

1.  Postliver Transplantation Rhino-Orbital Mucormycosis, an Unexpected Cause of a Downhill Course.

Authors:  Swapnali Sabhapandit; Mithun Sharma; Anuradha Sekaran; Balachandran Menon; Anand Kulkarni; Soumya Tr; Padaki Nagaraja Rao; Duvurr Nageshwar Reddy
Journal:  Case Reports Hepatol       Date:  2022-05-28

Review 2.  Cutaneous mucormycosis postcosmetic surgery: A case report and review of the literature.

Authors:  Khaled Al-Tarrah; Mahmoud Abdelaty; Ahmad Behbahani; Eman Mokaddas; Helmy Soliman; Ahdi Albader
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

3.  Initial sirolimus dosage recommendations for pediatric patients with PIK3CD mutation-related immunodeficiency disease.

Authors:  Xiao Chen; Jinglin Wang; Jianger Lan; Xilin Ge; Hong Xu; Yu Zhang; Zhiping Li
Journal:  Front Pharmacol       Date:  2022-09-14       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.